Major depressive disorder: Mechanism-based prescribing for personalized medicine

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 875-888

  Saltiel, Philip F ^a   Silvershein, Daniel I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Individualized pharmacotherapy; MDD; Patient specific profile; Tailored pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMFEBUTAMONE; AMITRIPTYLINE; ATOMOXETINE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DONEPEZIL; DOXEPIN; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; GALANTAMINE; IMIPRAMINE; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; NORADRENALIN TRANSPORTER; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE; VORTIOXETINE; ZIPRASIDONE;

ANXIETY DISORDER; ARTICLE; BRAIN FUNCTION; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; EXECUTIVE FUNCTION; FATIGUE; FUNCTIONAL ASSESSMENT; HUMAN; INSOMNIA; MAJOR DEPRESSION; MOOD DISORDER; NEUROBIOLOGY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRESCRIPTION; PREVALENCE; PROTEIN TARGETING; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; REMISSION; SLEEP WAKING CYCLE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 84929163539     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S73261     Document Type: Article

References (134)

1. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11:129.
2. Marcus M, Yasamy MT, van Ommeren M, Chisholm D, Saxena S; WHO Department of Mental Health and Substance Abuse. Depression: A Global Public Health Concern. Geneva, Switzerland: World Health Organization; 2012. Available from: http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf. Accessed August 12, 2013.
3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627.
4. Centers for Disease Control and Prevention (CDC). Current depression among adults – United States, 2006 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59(38):1229–1235.
5. Howden LM, Meyer JA. Age and Sex Composition: 2010. 2010 Census Briefs. Washington, DC: US Census Bureau; 2011. Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed August 12, 2013.
6. McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243–259.
7. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35(1):1–14.
8. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465–1475.
9. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010. Available from: http://www.guideline.gov/content.aspx?id=24158. Accessed November 21, 2014.
10. Mitchell J, Trangle M, Degnan B, et al. Adult Depression in Primary Care. Bloomington, MN: Institute for Clinical Systems Improvement; 2013 [updated September 2013]. Available from: https://www.icsi.org/_asset/fnhdm3/Depr-Interactive0512b.pdf. Accessed April 5, 2014.
11. Patten SB, Kennedy SH, Lam RW, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord. 2009;117 Suppl 1:S5–S14.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
13. Ani C, Bazargan M, Hindman D, et al. Depression symptomatology and diagnosis: discordance between patients and physicians in primary care settings. BMC Fam Pract. 2008;9:1.
14. The Department of Veterans Affairs, Department of Defense. Clinical Practice Guideline for Management of Major Depressive Disorder (MDD). Washington, DC: Department of Veterans Affairs, Department of Defense; 2009. Available from: http://www.healthquality.va.gov/mdd/mdd_full09_c.pdf. Accessed November 15, 2014.
15. Paykel ES. Partial remission, residual symptoms, and relapse in depression. Dialogues Clin Neurosci. 2008;10(4):431–437.
16. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry. 2007;29(5):409–416.
17. Rubio JM, Markowitz JC, Alegria A, et al. Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. Depress Anxiety. 2011;28(8):622–631.
18. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–186.
19. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: implications for how remission from depression should be defined. Psychiatry Res. 2006;141(2):185–191.
20. Rush AJ, Kraemer HC, Sackeim HA, et al; ACNP Task Force. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841–1853.
21. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52 Suppl:28–34.
22. Sibille E, French B. Biological substrates underpinning diagnosis of major depression. Int J Neuropsychopharmacol. 2013;16(8):1893–1909.
23. Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg depression rating scale. J Clin Psychiatry. 2004;65(2):163–168.
24. Zimmerman M, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA. Symptom differences between depressed outpatients who are in remission according to the Hamilton Depression Rating Scale who do and do not consider themselves to be in remission. J Affect Disord. 2012;142(1–3):77–81.
25. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
26. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459.
27. Zisook S, Ganadjian K, Moutier C, Prather R, Rao S. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned. J Clin Psychiatry. 2008;69(7):1184–1185.
28. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2–3):97–108.
29. Conradi HJ, Ormel J, de Jonge P. Symptom profiles of DSM-IV-defined remission, recovery, relapse, and recurrence of depression: the role of the core symptoms. Depress Anxiety. 2012;29(7):638–645.
30. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150.
31. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67(11):1754–1759.
32. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat. 2012;2012:630206.
33. Banerjee S, Chatterji P, Lahiri K. Identifying the mechanisms for workplace burden of psychiatric illness. Med Care. 2014;52(2):112–120.
34. Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom of major depressive disorder: overview and the role of bupropion. Expert Rev Neurother. 2007;7(10):1251–1263.
35. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):93–105.
36. Tritschler L, Felice D, Colle R, et al. Vortioxetine for the treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014;7(6):731–745.
37. Schultz E, Malone DA Jr. A practical approach to prescribing antidepressants. Cleve Clin J Med. 2013;80(10):625–631.
38. Thase ME, Chen D, Edwards J, Ruth A. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(6):351–356.
39. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother. 2009;9(7):975–984.
40. Jeon HJ, Fava M, Mischoulon D, et al. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial. Int Clin Psychopharmacol. 2014;29(6):332–338.
41. Greer TL, Sunderajan P, Grannemann BD, Kurian BT, Trivedi MH. Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? Depress Res Treat. 2014;2014:627863.
42. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
43. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. Psychomotor depressive symptoms may differentially respond to venlafaxine. Int Clin Psychopharmacol. 2013;28(3):121–126.
44. Cooper JA, Tucker VL, Papakostas GI. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol. 2014;28(2):118–124.
45. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153–159.
46. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Randomized, double-blind, head-to-head, flexible-dose study of vortioxetine vs escitalopram in sexual functioning in adults with well-controlled major depressive disorder experiencing treatment-emergent sexual dysfunction. Poster presented at: 29th CINP World Congress of Neuropsychopharmacology; June 22–26, 2014; Vancouver, Canada.
47. Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–482.
48. Weizman S, Gonda X, Dome P, Faludi G. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol Hung. 2012;14(2):87–101.
49. Aziz R, Steffens DC. What are the causes of late-life depression? Psychiatr Clin North Am. 2013;36(4):497–516.
50. Nestler EJ. Epigenetic mechanisms of depression. JAMA Psychiatry. 2014;71(4):454–456.
51. Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci. 2012;16(1):61–71.
52. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2013;18(5):595–606.
53. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64 Suppl 14: 6–17.
54. Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74 Suppl 2:19–24.
55. Kuhn M, Popovic A, Pezawas L. Neuroplasticity and memory formation in major depressive disorder: an imaging genetics perspective on serotonin and BDNF. Restor Neurol Neurosci. 2014;32(1):25–49.
56. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719–3735.
57. McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 2009;34(1):41–54.
58. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6):899–905.
59. Guo W, Liu F, Yu M, et al. Functional and anatomical brain deficits in drug-naive major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:1–6.
60. Lum CT, Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr. 2012;17(3):107–120.
61. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013.
62. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1–2):93–118.
63. Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120536.
64. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:54–63.
65. Moret C, Briley M. The importance of norepinephrine in depression. Neuropsychiatr Dis Treat. 2011;7 Suppl 1:9–13.
66. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327–337.
67. O’Leary OF, Cryan JF. Chapter 4.13 – The behavioral genetics of serotonin: relevance to anxiety and depression. In: Muller CP, Jacobs BL, eds. Handbook of Behavioral Neuroscience. Vol 21. London, UK: Elsevier; 2010:749–789.
68. Aman TK, Shen RY, Haj-Dahmane S. D2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther. 2007;320(1):376–385.
69. Adell A, Bortolozzi A, Diaz-Mataix L, Santana N, Celada P, Artigas F. Chapter 2.8 – Serotonin interactions with other transmitter systems. In: Muller CP, Jacobs BL, eds. Handbook of Behavioral Neuroscience. Vol 21. London, UK: Elsevier; 2010:259–276.
70. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014;19(2):121–133.
71. Stahl S, Briley M. Understanding pain in depression. Hum Psychopharmacol. 2004;19 Suppl 1:S9–S13.
72. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013;14(5):578–585.
73. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758.
74. Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12r01420.
75. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305–1322.
76. Ciraulo DA, Barnhill JG, Jaffe JH. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther. 1988;43(5):509–518.
77. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45.
78. Joel I, Begley AE, Mulsant BH, et al; IRL GREY Investigative Team. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry. 2014;22(2):167–176.
79. Pan YJ, Liu SK, Yeh LL. Factors affecting early attrition and later treatment course of antidepressant treatment of depression in naturalistic settings: an 18-month nationwide population-based study. J Psychiatr Res. 2013;47(7):916–925.
80. Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267–284.
81. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96–106.
82. Magura S, Rosenblum A, Fong C. Factors associated with medication adherence among psychiatric outpatients at substance abuse risk. Open Addict J. 2011;4:58–64.
83. Preston TC, Shelton RC. Treatment resistant depression: strategies for primary care. Curr Psychiatry Rep. 2013;15(7):370.
84. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27 Suppl 1:S29–S37.
85. Wright BM, Eiland EH III, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344–359.
86. Chang TE, Jing Y, Yeung AS, et al. Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial. Gen Hosp Psychiatry. 2012;34(2):105–112.
87. Shao L, Li W, Xie Q, Yin H. Triple reuptake inhibitors: a patent review (2006–2012). Expert Opin Ther Pat. 2014;24(2):131–154.
88. Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012;46(1):64–71.
89. Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat. 2012;8:123–130.
90. Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:349–354.
91. Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol. 1996;10(1):16–27.
92. Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2013;16(5):1115–1127.
93. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433–1442.
94. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–3221.
95. Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–675.
96. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry. 2005;58(10):831–837.
97. Weber S, Volynets V, Kanuri G, Bergheim I, Bischoff SC. Treatment with the 5-HT3 antagonist tropisetron modulates glucose-induced obesity in mice. Int J Obes (Lond). 2009;33(12):1339–1347.
98. Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2014;29(1):36–44.
99. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(1):60–82.
100. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011;1(3):81–87.
101. Hammar A, Sørensen L, Ardal G, et al. Enduring cognitive dysfunction in unipolar major depression: a test-retest study using the Stroop paradigm. Scand J Psychol. 2010;51(4):304–308.
102. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2–3):183–189.
103. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48.
104. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011;134(1–3):20–31.
105. Hammar A, Ardal G. Cognitive functioning in major depression – a summary. Front Hum Neurosci. 2009;3:26.
106. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur Psychiatry. 2013;28(6):349–355.
107. Harvey PO, Fossati P, Pochon JB, et al. Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage. 2005;26(3):860–869.
108. MacDonald AW 3rd, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288(5472):1835–1838.
109. Dell’Osso B, Cremaschi L, Spagnolin G, Ketter TA, Altamura AC. Augmentative dopaminergic interventions for treatment-resistant bipolar depression: a focus on dopamine agonists and stimulants. J Psychopathol. 2013;19:327–340.
110. Murrough JW, Wan LB, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2013;231(3):481–488.
111. Strzelecki D, Tabaszewska A, Barszcz Z, Józefowicz O, Kropiwnicki P, Rabe-Jabłońska J. A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry Investig. 2013;10(4):421–424.
112. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223.
113. Iverson GL, Lam RW. Rapid screening for perceived cognitive impairment in major depressive disorder. Ann Clin Psychiatry. 2013;25(2):135–140.
114. Ferentinos PP, Kontaxakis VP, Havaki-Kontaxaki BJ, Dikeos DG, Papadimitriou GN. Fatigue and somatic anxiety in patients with major depression. Psychiatriki. 2009;20(4):312–318.
115. Fava M, Ball S, Nelson JC, et al. Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety. 2014;31(3):250–257.
116. Soyuer F, Şenol V. Functional outcome and depression in the elderly with or without fatigue. Arch Gerontol Geriatr. 2011;53(2):e164–e167.
117. Targum SD, Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci. 2011;8(10):40–43.
118. MacHale SM, Lawŕie SM, Cavanagh JT, et al. Cerebral perfusion in chronic fatigue syndrome and depression. Br J Psychiatry. 2000;176:550–556.
119. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350–1355.
120. McClung CA. How might circadian rhythms control mood? Let me count the ways… Biol Psychiatry. 2013;74(4):242–249.
121. Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality relationship. Sleep Med Rev. 2007;11(5):341–360.
122. Lai YC, Huang MC, Chen HC, et al. Familiality and clinical outcomes of sleep disturbances in major depressive and bipolar disorders. J Psychosom Res. 2014;76(1):61–67.
123. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol. 1986;22(1):97–99.
124. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry. 1997;58(8):348–350.
125. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24(12):726–731.
126. Santos Moraes WA, Burke PR, Coutinho PL, et al. Sedative antidepressants and insomnia. Rev Bras Psiquiatr. 2011;33(1):91–95.
127. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–1049.
128. Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010;24(8):713–720.
129. Maclean L, Ahmedani BK. Sertraline and low-dose doxepin treatment in severe agitated-anxious depression with significant gastrointestinal complaints: two case reports. Prim Care Companion CNS Disord. 2011;13(4) pii: PCC.12r01420.
130. Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol. 2009;11(5):349–357.
131. De Berardis D, Marini S, Fornaro M, et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci. 2013;14(6):12458–12483.
132. Kennedy SH, Cyriac A. A dimensional approach to measuring antidepressant response: implications for agomelatine. Psychology. 2012;3(10):864–869.
133. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365–375.
134. Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15(9):15924–15950.